Management of Small Bowel Neuroendocrine Tumours: 10 Years’ Experience at a Tertiary Referral Centre
Cancers · 06.09.2023 · 15 (18) · 4438
DOI: 10.3390/cancers15184438 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancers, online erschienen am 06.09.2023. Verfasst von Ashley K Clift und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0HS, UK. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 81 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Heinz Horst Deichmann Foundation, European Union FP7, Heinz-Horst Deichmann Foundation.
Abstract (Originalsprache)
Background
Neuroendocrine tumours (NET) arising from the small bowel are clinically challenging and are often diagnosed at advanced stages. Disease control with surgery alone can be demanding. Multimodal treatment concepts integrating surgery and non-surgical modalities could be of benefit.
Method
Retrospective review of consecutive adult patients with SB NET treated at Imperial College Healthcare NHS Trust between 1 January 2010 and 31 December 2019. Data regarding clinicopathological characteristics, treatments, and disease trajectory were extracted and summarised. Overall and progression/recurrence-free survival were estimated at 5 and 10 years.
Results
154 patients were identified, with a median age of 64 years (range 33–87); 135/154 (87.7%) had stage III/IV disease at diagnosis. Surgery was used in 125 individuals (81.2%), typically with either segmental small bowel resection (60.8%) or right hemicolectomy (33.6%) and mesenteric lymphadenectomy for the primary tumour. Systemic and/or liver-directed therapies were used in 126 (81.8%); 60 (47.6%) had more than one line of non-surgical treatment. Median follow-up was 67.2 months (range 3.1–310.4); overall survival at 5 and 10 years was 91.0% (95% CI: 84.9–94.7%) and 82.5% (95% CI: 72.9–88.9%), respectively. Imaging-based median progression-free survival was 42.7 months (95% CI: 24.7 to 72.4); 5-year progression-free survival was 63.4% (95% CI: 55.0–70.6%); 10-year progression-free survival was 18.7% (95% CI: 12.4–26.1). Nineteen patients (12.3%) reached 10 years follow-up without disease recurrence and therefore were considered cured.
Conclusions
Most patients with SB NET present in a metastasised stage. Multimodal treatment concepts may be associated with excellent clinical outcomes. Future work should explore optimal approaches to treatment sequencing and patient selection.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery and Cancer, Imperial College London, Hammersmith Campus, Du Cane Road, London W12 0HS, UK.
- CRUK Oxford Centre, Department of Oncology, University of Oxford, Oxford OX1 2JD, UK.
- Department of Surgery, Ealing Hospital, London North West University Healthcare NHS Trust, London HA1 3UJ, UK.
- Department of Surgery, University College London Hospitals NHS Foundation Trust London, London NW1 2BU, UK.
- Department of Gastroenterology, St Mark's Hospital, London North West University Health Care NHS Trust, London HA1 3UJ, UK.
- Department of Nuclear Medicine, University College London Hospitals NHS Foundation Trust London, London NW1 2BU, UK.
ORCID-Profile: Nagy Habib, Andrea Frilling
Förderung
- Heinz Horst Deichmann Foundation
- European Union FP7
- Heinz-Horst Deichmann Foundation
Zitieren
APA
Clift, A. K., Drymousis, P., von Roon, A., Humphries, A., Goldin, R., Bomanji, J., Leaman, S., Wasan, H., Habib, N., & Frilling, A. (2023). Management of Small Bowel Neuroendocrine Tumours: 10 Years’ Experience at a Tertiary Referral Centre. Cancers, 15(18), 4438. https://doi.org/10.3390/cancers15184438
Vancouver
Clift AK, Drymousis P, von Roon A, Humphries A, Goldin R, Bomanji J, et al. Management of Small Bowel Neuroendocrine Tumours: 10 Years’ Experience at a Tertiary Referral Centre. Cancers. 2023;15(18):4438. doi:10.3390/cancers15184438
BibTeX
@article{Clift2023,
author = {Clift, Ashley K and Drymousis, Panagiotis and von Roon, Alexander and Humphries, Adam and Goldin, Robert and Bomanji, Jamshed and Leaman, Sydney and Wasan, Harpreet and Habib, Nagy and Frilling, Andrea},
title = {Management of Small Bowel Neuroendocrine Tumours: 10 Years’ Experience at a Tertiary Referral Centre},
journal = {Cancers},
year = {2023},
volume = {15},
number = {18},
pages = {4438},
doi = {10.3390/cancers15184438}
}
EUVIMED